Days af­ter buy­out news, Vi­for out­lines plan to of­fload 'non-core' fin­ished drug man­u­fac­tur­ing wing

Aus­tralian firm CSL paid a steep price ear­li­er this week for Vi­for Phar­ma and its pipeline of iron and kid­ney drugs. Look­ing to en­sure it starts its next phase as bat­tle-ready as pos­si­ble, Vi­for will now dump its “non-core” man­u­fac­tur­ing busi­ness as it slims down be­fore the merge.

Vi­for Phar­ma will of­fload its fin­ished drug man­u­fac­tur­ing wing to Swiss CD­MO Cor­den­Phar­ma in a deal de­signed to stream­line the biotech’s busi­ness as it awaits reg­u­la­to­ry ap­proval for a $11.7 bil­lion buy­out by CSL an­nounced ear­li­er this week.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN